George A. Scangos

Chief executive: Biogen Inc. (before 2014 to 6 Jan 2017); Biogen Inc. (before 2014 to 21 Jul 2016)

8commitments announced

6with a clear outcome

6met on time

–rate shown after 15 outcomes

Commitments are credited to the chief executive in office on the day they were announced. Where a deadline fell after the leader left, the entry is marked. Sources for each leadership change: Biogen Inc. filing, Biogen Inc. filing.

Commitments announced under George A. Scangos

Biogenannounced 3 May 2016	Complete the spin-off of the hemophilia business due after leader left	Met31 Mar 2017
Biogenannounced 3 May 2016	Initiate clinical development of longer acting therapies utilizing XTEN technology due after leader left	No record found30 Jun 2017
Biogenannounced 3 May 2016	Complete the spin-off of the hemophilia business due after leader left	Met31 Mar 2017
Biogenannounced 3 May 2016	Initiate clinical development of longer acting therapies utilizing XTEN technology due after leader left	No record found30 Jun 2017
Biogen Inc.announced 27 Jan 2016	Report Phase 2 data for anti-LINGO in multiple sclerosis	Met30 Jun 2016
Biogen Inc.announced 27 Jan 2016	Launch three new products: BENEPALI, ZINBRYTA, and an infliximab biosimilar	Met31 Dec 2016
Biogen Inc.announced 27 Jan 2016	Report Phase 2 data for anti-LINGO in multiple sclerosis	Met30 Jun 2016
Biogen Inc.announced 27 Jan 2016	Launch three new products: BENEPALI, ZINBRYTA, and an infliximab biosimilar due after leader left	Met31 Dec 2016

Is this record wrong, or are you George A. Scangos? Add a statement or ask for a correction.

Commitments announced under George A. Scangos

The Deadline Report